Based on the significant clinical benefit of amivantamab–chemotherapy in NSCLC patients harboring EGFR exon 20 insertion mutations, it would be important to reduce the cost of amivantamab or combine it with other drugs to improve its effectiveness. Here, EGFR is linked to non-small cell lung carcinoma.